



EY Entrepreneur
of the year-2013



FROST & SULLIVAN
Best Practices-2013



Business today/YES bank
Excellence Awards-2013



Date: 26 October 2026

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: OUTCOME OF THE BOARD MEETING HELD TODAY, i.e., October 26, 2026

Dear Sir/Madam,

Pursuant to Regulation 30 read with Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("**LODR**") we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., October 26, 2026, *inter alia*, duly approved and took on record Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026.

In this regard, the following documents are enclosed:

- A copy of the said financial results along with Limited review report pursuant to Regulation 33 and Regulation 52 of the SEBI Listing Regulations. The limited review reports are submitted with unmodified opinion(s) (free from any qualifications).
- Details as per Regulation 52(4) of SEBI Listing Regulations.

The meeting of the Board of Directors commenced at 11:00 A.M. and concluded at 01:40 P.M.

This is for your information and record.

Thanking You,

For Eris Lifesciences Limited

Milind

Talegaonkar

Digitally signed by
Milind Talegaonkar
Date: 2026.10.26
13:45:24 +05'30'

Milind Talegaonkar

Company Secretary & Compliance Officer

Membership No: A26493

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

Walker ChandioK & Co LLP

Block No. D/15th Floor,
Cabin No. A8 to A10
"West Gate" Near YMCA Club,
S.G Highway, Sarkhej Road,
Ahmedabad-380015
Gujarat, India

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Eris Lifesciences Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Eris Lifesciences Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and joint venture (refer Annexure 1 for the list of subsidiaries and joint venture included in the Statement) for the quarter ended 30 September 2026 and the consolidated year to date results for the period 1 April 2026 to 30 September 2026 being submitted by the Holding Company pursuant to the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker ChandioK & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Walker Chandiok & Co LLP

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We did not review the interim financial results of 5 subsidiaries included in the Statement, whose financial information reflects total assets of ₹ 1,474.07 Crores as at 30 September 2026, and total revenues of ₹ 163.96 Crores and ₹ 275.14 Crores, total net profit after tax of ₹ 30.66 Crores and ₹ 42.44 Crores, total comprehensive income of ₹ 30.07 Crores and ₹ 41.79 Crores for the quarter and six-month period ended on 30 September 2026, respectively, and net cash inflows of ₹ 7.16 Crores for the period ended 30 September 2026, as considered in the Statement. The Statement also includes the Group's share of net loss after tax of ₹ 0.90 Crores and ₹ 1.30 Crores and total comprehensive loss of ₹ 0.90 Crores and ₹ 1.30 Crores for the quarter and six-month period ended on 30 September 2026, respectively, as considered in the Statement, in respect of one joint venture, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and joint venture is based solely on the review reports of such other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of these matter with respect to our reliance on the work done by and the reports of the other auditors.

For **Walker Chandiok & Co LLP**

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Ashish
Gupta

Digitally signed by
Ashish Gupta
Date: 2026.10.26
13:12:37 +05'30'



Ashish Gupta

Partner

Membership No.: 504662

UDIN: 26504662LAQQUU4575

Place: New Delhi

Date: 26 October 2026

Annexure 1 to the Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

List of entities included in the Statement

Holding Company

Sr. No.	Name of entity
1	Eris Lifesciences Limited

Subsidiaries

Sr. No.	Name of entities
1	Eris Therapeutics Limited
2	Eris Oaknet Healthcare Private Limited (Step-down subsidiary)
3	Eris Healthcare Private Limited
4	Eris M. J. Biopharm Private Limited
5	Eris Pharmaceuticals Limited
6	Eris Bionxt Private Limited
7	Swiss Parenterals Limited

Joint venture

Sr. No.	Name of entity
1	Levim Lifetech Private Limited



EY Entrepreneur
of the year-2013FROST & SULLIVAN
Best Practices-2013Business today/YES bank
Excellence Awards-2013

Statement of Unaudited Consolidated Financial results for the quarter and half year ended September 30, 2026

Sr. No.	Particulars	[Rs in Crore except per share data]					
		For quarter ended		For half year ended		For year ended	
		September 30, 2026 (Unaudited)	June 30, 2026 (Unaudited)	September 30, 2025 (Unaudited)	September 30, 2026 (Unaudited)	September 30, 2025 (Unaudited)	March 31, 2026 (Audited)
1	Income						
	Revenue from operations						
	Sale of products	889.50	869.03	790.15	1,758.53	1,561.71	3,114.89
	Other operating income	2.87	4.22	2.26	7.09	3.70	14.53
	Total Revenue from operations	892.37	873.25	792.41	1,765.62	1,565.41	3,129.42
	Other income	3.20	2.39	2.81	5.59	5.50	7.75
	Total income	895.57	875.64	795.22	1,771.21	1,570.91	3,137.17
2	Expenses						
	Cost of materials consumed	107.86	94.27	82.58	202.13	152.68	326.65
	Purchase of stock-in-trade	167.72	131.12	146.09	298.84	250.35	490.56
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(49.85)	13.86	(26.26)	(35.99)	(15.98)	(21.61)
	Employee benefits expense	149.19	153.42	137.45	302.61	281.88	556.81
	Finance costs	46.42	46.65	49.55	93.07	98.23	192.67
	Depreciation and amortisation expense	73.42	72.07	69.08	145.49	139.59	279.50
	Other expenses	208.10	184.36	164.34	392.46	331.56	656.90
	Total expenses	702.86	695.75	622.83	1,398.61	1,238.31	2,481.48
3	Profit before share of profit from investment in joint venture, exceptional item and tax for the period / year (1-2)	192.71	179.89	172.39	372.60	332.60	655.69
4	Share of loss/ (profit) from investment in joint venture, net of tax	0.90	0.40	(0.28)	1.30	(1.17)	(0.09)
5	Profit before exceptional item and tax for the period / year (3-4)	191.81	179.49	172.67	371.30	333.77	655.78
6	Exceptional items (Refer note 5)	35.90	-	-	35.90	-	17.24
7	Profit before tax for the period / year (5-6)	155.91	179.49	172.67	335.40	333.77	638.54
8	Tax Expense						
	Current tax	(64.78)	31.10	71.18	(33.68)	127.49	157.41
	Deferred tax	33.55	5.07	(32.98)	38.62	(53.29)	(166.38)
	Total tax expense (Refer note 7)	(31.23)	36.17	38.20	4.94	74.20	(8.97)
9	Net profit for the period / year (7-8)	187.14	143.32	134.47	330.46	259.57	647.51
	Attributable to :						
	- Owners of the Company	183.82	142.39	120.19	326.21	238.18	619.52
	- Non controlling interest	3.32	0.93	14.28	4.25	21.39	27.99
10	Other comprehensive income/(loss)						
	Items that will not be reclassified to gain or (loss)						
	Re-measurement gains / (losses) on defined benefit plans	0.17	0.16	(0.84)	0.33	(1.68)	0.12
	Income tax effect	(0.04)	(0.04)	0.27	(0.08)	0.54	0.22
	Items that will be reclassified to profit or loss						
	Net movement on effective portion of cash flow hedges	(1.70)	(0.03)	-	(1.73)	-	(2.42)
	Income tax effect	0.41	(0.03)	-	0.38	-	0.64
	Other comprehensive income/(loss) for the period / year, net of tax	(1.16)	0.06	(0.57)	(1.10)	(1.14)	(1.44)
	Attributable to :						
	- Owners of the Company	(1.16)	0.06	(0.56)	(1.10)	(1.12)	(1.47)
	- Non controlling interest	-	-	(0.01)	-	(0.02)	0.03
11	Total comprehensive income						
	Attributable to :						
	- Owners of the Company	182.66	142.45	119.63	325.11	237.06	618.05
	- Non controlling interest	3.32	0.93	14.27	4.25	21.37	28.02
	Total comprehensive income for the period / year (9+10)	185.98	143.38	133.90	329.36	258.43	646.07
12	Paid Up Equity Share Capital (Face Value of Rs 1 each)	13.87	13.86	13.62	13.87	13.62	13.85
13	Other Equity						3,888.82
14	Earnings Per Share (of Rs 1 each) (not annualised) :						
	Basic	13.26	10.28	8.82	23.54	17.49	45.33
	Diluted	13.25	10.26	8.81	23.53	17.46	45.26



Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
 Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

Statement of Consolidated Assets and Liabilities as at September 30, 2026

[Rs in Crore]

Particulars	As at September 30, 2026	As at March 31, 2026
	(Unaudited)	(Audited)
I. ASSETS :		
Non Current Assets		
(a) Property, plant and equipment	670.42	661.52
(b) Capital work in progress	394.94	171.47
(c) Right-of-use assets	45.21	46.85
(d) Goodwill	691.78	911.97
(e) Other intangible assets	3,455.78	3,567.22
(f) Intangible assets under development	6.05	-
(g) Investments accounted using equity method	50.28	51.58
(h) Financial assets		
(i) Investments	10.00	9.98
(ii) Loans	1.12	1.12
(iii) Other financial assets	11.40	9.83
(i) Non current tax assets (net)	51.46	40.66
(j) Deferred tax assets (net)	298.41	242.91
(k) Other assets	93.49	110.55
Total Non-current assets	5,780.34	5,825.66
Current assets		
(a) Inventories	474.47	436.82
(b) Financial assets		
(i) Trade receivables	631.88	680.34
(ii) Cash and cash equivalents	238.09	54.74
(iii) Bank balances other than (iii) above	16.04	12.56
(iv) Loans	76.86	52.75
(v) Other financial assets	14.68	9.08
(c) Other assets	348.84	293.56
Total Current assets	1,800.86	1,539.85
TOTAL- ASSETS	7,581.20	7,365.51
II. EQUITY AND LIABILITIES :		
Equity		
(a) Equity share capital	13.87	13.85
(b) Other equity	4,130.47	3,888.82
Equity attributable to the owners of the company	4,144.34	3,902.67
(c) Non-controlling interest	(2.76)	(7.01)
Total Equity	4,141.58	3,895.66
Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	427.46	955.83
(ii) Lease liabilities	37.59	40.19
(iii) Other financial liabilities	1.07	1.07
(b) Other liabilities	3.52	3.80
(c) Provisions	110.13	86.78
(d) Deferred tax liabilities (net)	178.71	305.08
Total Non-Current liabilities	758.48	1,392.75
Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	1,954.34	1,353.85
(ii) Lease liabilities	10.11	8.75
(iii) Trade payables		
i) Total outstanding dues of micro enterprises and small enterprises	32.76	8.76
ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	422.98	320.89
(iv) Other financial liabilities	146.37	197.74
(b) Other liabilities	59.04	71.64
(c) Provisions	41.72	37.71
(d) Current tax liabilities (net)	13.82	77.76
Total Current liabilities	2,681.14	2,077.10
Total liabilities	3,439.62	3,469.85
TOTAL- EQUITY AND LIABILITIES	7,581.20	7,365.51



Unaudited Statement of consolidated cash flows for the half year ended September 30, 2026

[Rs in Crore]

Particulars	For the half year ended September 30, 2026 (Unaudited)	For the half year ended September 30, 2025 (Unaudited)
<u>A. Cash flow from operating activities</u>		
Profit before tax	335.40	333.77
Adjustments for :		
Depreciation and amortisation expense	145.49	139.59
Net loss on property plant and equipment	(0.02)	0.03
Finance costs	93.07	98.23
Interest income	(3.74)	(1.44)
Share of profit of an joint venture, net of tax	1.30	(1.17)
Reversal of expected credit loss	(8.56)	-
Deferred capital subsidy	(0.36)	(0.33)
Net (gain) on sale of investments carried at fair value through profit or loss	(0.47)	(0.68)
Share based payment expense	4.40	4.00
Operating profit before working capital changes	566.51	572.00
Changes in working capital:		
Adjustments for (increase) / decrease in operating assets:		
Trade receivables	57.02	(186.78)
Inventories	(37.65)	(73.85)
Financial assets	(5.34)	(6.00)
Other assets	(50.23)	(54.77)
Adjustments for increase / (decrease) in operating liabilities:		
Trade payables	126.10	66.36
Financial liabilities	5.88	4.42
Provisions	27.69	(13.50)
Other liabilities	(11.80)	(19.99)
Cash generated from operations	678.18	287.89
Net income tax paid	(41.05)	(48.84)
Net cash generated from operating activities (A)	637.13	239.05
<u>B. Cash flow from investing activities</u>		
Purchase of property, plant and equipment (including intangible assets, intangible assets under development, capital advances and capital creditors)	(220.40)	(116.87)
Proceeds from sale of property plant and equipment	(0.02)	0.09
Consideration paid towards business combination (Including transaction costs)	(39.00)	-
Proceeds from redemption of mutual funds (net)	0.47	0.68
Proceeds from redemption of investment in bonds	-	0.52
Investments in compulsory convertible debentures purchased from minority interest in subsidiary	-	(34.65)
Loan given to joint venture	(24.11)	0.14
Proceeds of bank balances not considered as cash and cash equivalents	(3.48)	9.40
Interest received	1.88	1.44
Net cash used in investing activities (B)	(284.66)	(139.25)
<u>C. Cash flow from financing activities</u>		
Proceeds from long term borrowings	231.32	-
Repayment of long term borrowings	(149.58)	(143.23)
Proceeds/ (repayment) from short term borrowings (net)	(9.62)	55.94
Interest paid	(144.15)	(152.88)
Payment for lease liability (including interest)	(8.56)	(6.38)
Proceeds from issue of equity share capital (Employee stock options plan)	11.35	3.07
Dividend paid	(99.88)	-
Net cash used in financing activities (C)	(169.12)	(243.48)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	183.35	(143.68)
Cash and cash equivalents at the beginning of the period	54.74	199.74
Cash and cash equivalents at end of the period	238.09	56.06



Additional information pursuant to Regulation 52(4) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 as amended for the quarter and half year ended September 30, 2026

Particulars	Consolidated					
	For quarter ended			For half year ended		For year ended
	September 30, 2026 (Unaudited)	June 30, 2026 (Unaudited)	September 30, 2025 (Unaudited)	September 30, 2026 (Unaudited)	September 30, 2025 (Unaudited)	March 31, 2026 (Audited)
Debt – Equity Ratio (in times) (Total Debt(including lease liabilities)/Total Equity)	0.59	0.64	0.68	0.59	0.68	0.61
Debt Service Coverage Ratio (in times) (Profit after tax-Other income+ Depreciation and amortisation expense+Finance Costs+Committed Principal repayments made during the period for long term loans/Finance Costs +Committed Principal repayments made during the period for long term loans)	3.12	2.75	2.65	2.94	2.63	2.91
Interest service coverage ratio (in times) (Earnings before share of profit from joint venture, exceptional items, Interest and Tax/Finance Costs)	5.15	4.86	4.48	5.00	4.39	4.40
Outstanding redeemable preference shares (quantity and value)	NA	NA	NA	NA	NA	NA
Capital redemption reserve/debenture redemption reserve (Rs in crore)	0.17	0.17	0.17	0.17	0.17	0.17
Net worth (Rs in crore)	4,141.57	3,944.22	3,503.48	4,141.57	3,503.48	3,895.66
Net profit after tax (Rs in crore)	187.14	143.32	134.47	330.46	259.57	647.51
Earnings per share						
Basic	13.26	10.28	8.82	23.54	17.49	45.33
Diluted	13.25	10.26	8.81	23.53	17.46	45.26
Current Ratio (in times) (Current Assets/Current Liabilities)	0.67	0.60	0.91	0.67	0.91	0.74
Long term debt to working capital (in times) (Long-term borrowing+Lease liabilities including its current maturity)/Current Assets-Current liabilities (excluding current maturity)	3.10	4.59	11.36	3.10	11.36	5.13
Bad debts to account receivable ratio (in times) (Bad debts/Trade receivables)	Nil	Nil	Nil	Nil	Nil	Nil
Current liability ratio (in times) (Current liabilities/Total liabilities)	0.78	0.77	0.42	0.78	0.42	0.60
Total debts to total assets (in times) (Total Debt (including lease liabilities)/Total Assets)	0.32	0.33	0.33	0.32	0.33	0.32
Debtors' turnover* (in times) (Sales/Trade receivables)	5.24	4.32	4.63	5.24	4.63	4.58
Inventory Turnover* (in times) (Cost of goods sold/Average Inventory)	1.98	1.93	2.21	1.98	2.21	2.06
Operating margin percent (Earnings before share of profit/ (loss) from joint venture, exceptional items, Finance cost and Tax/Revenue from Operations)	26.80%	25.94%	28.01%	26.37%	27.52%	27.11%
Net profit margin percent (Profit after tax/Revenue from Operations)	20.97%	16.41%	16.97%	18.72%	16.58%	20.69%

*Quarterly ratios based on trailing twelve months values.




Notes to Unaudited Consolidated Financial results

- 1 The above statement of Unaudited Consolidated Financial results ("the Statement") have been recommended by the Audit Committee and approved by the Board of Directors at their meetings held on October 26, 2026.
- 2 The Unaudited Consolidated Financial results of the Holding Company have been prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards ('Ind AS') 34, Interim Financial Reporting (Ind AS 34) as prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (as amended).
- 3 The Holding Company has issued and allotted 1,95,682 ordinary shares of Rs 1 each under the Company's Employee Stock Option Scheme 2021 for the half year ended September 30, 2026.
- 4 The Holding Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
- 5 (A) Exceptional items for the period ended September 30, 2026 comprise of settlement with customers for supply of products, which were launched at risk in earlier periods. The Company has recognised a write down of amounts due from such customers of Rs. 35.90 Crore (net of collections, provisions made in the past) as part of such settlement.

(B) Effective from November 21, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Holding Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability and leave liability arising out of past service cost by Rs 17.24 Crores primarily arising due to change in definition of "wages" for employees and contract labours. The Holding Company has presented such incremental impact under "Exceptional Item" in the consolidated financial results for the year ended March 31, 2026.

- 6 For the Financial year ended March 31, 2026, the Holding Company has completed acquisition of the Branded Probiotics Business from Velbiom Probiotics Private Limited for a consideration of Rs 50 Crores on a slump sale basis. The acquisition was completed on March 31, 2026. The Holding Company is in the process of making final determination of fair values of identified assets and liabilities for the purpose of purchase price allocation.
- 7 Aprica Healthcare Limited (AHL), Eris Oaknet Healthcare Private Limited (EOHPL) and Eris Therapeutics Limited (ETL) had filed a Scheme of Arrangement ("Scheme") under Sections 230 - 232 read with Section 66 and other applicable provisions of the Companies Act, 2013, for the amalgamation of Aprica Healthcare Limited (AHL) and the demerger of the "Domestic Business" of Eris Oaknet Healthcare Private Limited (EOHPL) (collectively, the "Amalgamating Companies") into Eris Therapeutics Limited (ETL) (the "Resulting Company" and the "Amalgamated Company"). The Scheme was approved by the National Company Law Tribunal (NCLT) vide its order dated 24 September 2026, with an appointed date of 1 April 2025. The Scheme became effective on 22 October 2026 upon filing thereof with the Registrar of Companies.

Pursuant to the Scheme of Arrangement, the business losses incurred by EOHPL in earlier years, on which deferred tax assets were not recognised in earlier years, can now be set off against the business profits of ETL and also amortisation of Brand assets have become tax deductible for ETL with effect from the Appointed date. Accordingly, the total tax effect in the consolidated financial results for the period ended 30 September 2026 is accounted for as current tax credit of Rs. 96 crores and deferred tax charge in Rs. 31 crores. The Goodwill amount from EOHPL and AHL in the consolidated financial statements as of 30 September 2026 has been adjusted for the deferred tax liabilities on brand assets amounting to Rs. 220 crores as on the Appointed date.



For Eris Lifesciences Limited

A handwritten signature in black ink, appearing to read "Amit Bakshi".

Amit Bakshi
Chairman and Managing Director
DIN : 01250925

Place: Ahmedabad
Date: October 26, 2026

Walker ChandioK & Co LLP

Block No. D/15th Floor,
Cabin No. A8 to A10
"West Gate" Near YMCA Club,
S.G Highway, Sarkhej Road,
Ahmedabad-380015
Gujarat, India

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Eris Lifesciences Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Eris Lifesciences Limited ('the Company') for the quarter ended 30 September 2026 and the year to date results for the period 1 April 2026 to 30 September 2026 being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker ChandioK & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Walker Chandiok & Co LLP

4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Walker Chandiok & Co LLP**

Chartered Accountants

Firm's Registration No.: 001076N/N500013

**Ashish
Gupta**

Digitally signed
by Ashish Gupta
Date: 2026.10.26
13:11:43 +05'30'

Ashish Gupta

Partner

Membership No.: 504662

UDIN: 26504662BRDUMC1900



Place: New Delhi

Date: 26 October 2026



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Eris Lifesciences Limited

Statement of Unaudited Standalone Financial Results for the Quarter and Half Year Ended September 30, 2026

Sr. No.	Particulars	[Rs. in Crore except per share data]					
		For quarter ended			For half year ended		For year ended
		September 30, 2026 (Unaudited)	June 30, 2026 (Unaudited)	September 30, 2025 (Unaudited)	September 30, 2026 (Unaudited)	September 30, 2025 (Unaudited)	March 31, 2026 (Audited)
1	Income						
	Revenue from Operations						
	Sale of products	472.46	433.81	637.58	906.27	1,205.48	1,779.77
	Other operating income	9.78	10.18	12.92	19.97	23.66	41.97
	Total Revenue from Operations	482.24	443.99	650.50	926.24	1,229.14	1,821.74
	Other Income	19.24	26.38	23.59	45.62	46.27	98.31
	Total Income	501.48	470.37	674.09	971.86	1,275.41	1,920.05
2	Expenses						
	Cost of materials consumed	18.74	19.99	20.29	38.73	44.41	83.99
	Purchase of stock-in-trade	141.62	128.10	134.83	269.72	241.52	478.22
	Changes in inventories of finished goods, stock-in-trade and work-in- progress	(12.28)	12.72	42.27	0.44	92.98	64.49
	Employee benefits expense	82.01	90.84	85.42	172.85	179.20	340.62
	Finance costs	42.06	42.16	46.50	84.22	91.64	179.54
	Depreciation and amortisation expense	40.88	39.98	39.30	80.86	76.90	154.38
	Other expenses	69.04	72.44	70.81	141.48	157.83	242.09
	Total expenses	382.07	406.23	439.42	788.30	884.48	1,543.33
3	Profit before exceptional items and tax for the period / year(1-2)	119.41	64.14	234.67	183.56	390.93	376.72
4	Exceptional items (Refer note 4)	35.90	-	-	35.90	-	14.67
5	Profit before tax for the period / year (3-4)	83.51	64.14	234.67	147.66	390.93	362.05
6	Tax expense						
	Current tax	13.85	10.23	40.91	24.08	68.08	60.96
	Deferred tax	(59.49)	5.61	44.19	(53.88)	73.29	57.04
	Total tax expense	(45.64)	15.84	85.10	(29.80)	141.37	118.00
7	Net profit for the period / year (5-6)	129.15	48.30	149.57	177.46	249.56	244.05
8	Other Comprehensive income/ (loss)						
	Items that will not be reclassified to profit or (loss)						
	Re-measurement gains / (losses) on defined benefit plans	0.17	0.16	(0.77)	0.33	(1.54)	0.65
	Income tax effect	(0.04)	(0.04)	0.27	(0.08)	0.54	0.04
	Net movement on effective portion of cash flow hedges	(0.94)	-	-	(0.94)	-	-
	Income tax effect	0.24	-	-	0.24	-	-
	Other Comprehensive income/(loss) for the period / year, net of tax	(0.57)	0.12	(0.50)	(0.45)	(1.00)	0.69
9	Total Comprehensive income for the period / year (7+8)	128.58	48.42	149.07	177.01	248.56	244.74
10	Paid Up Equity Share Capital (Face Value of Rs 1 each)	13.87	13.86	13.62	13.87	13.62	13.85
11	Other Equity						3,181.61
12	Earnings Per Share (of Rs 1 each) (not annualised) :						
	Basic	9.32	3.49	10.98	12.81	18.32	17.86
	Diluted	9.31	3.48	10.96	12.80	18.29	17.83



Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

Statement of Standalone Assets and Liabilities as at September 30, 2026

[Rs in Crore]

Particulars	As at September 30, 2026 (Unaudited)	As at March 31, 2026 (Audited)
I. ASSETS :		
Non Current Assets		
(a) Property, plant and equipment	103.71	99.64
(b) Right-of-use asset	22.01	24.55
(c) Goodwill	48.57	48.57
(d) Other intangible assets	2,112.38	2,179.79
(e) Intangible assets under development	6.05	-
(f) Financial assets		
(i) Investments	1,414.06	1,414.05
(ii) Loans	551.55	456.51
(iii) Other financial asset	5.04	265.93
(g) Non current tax assets (net)	30.67	30.02
(h) Deferred tax assets (net)	280.39	226.36
(i) Other non-current assets	5.01	9.71
Total Non Current Assets	4,579.44	4,755.13
Current Assets		
(a) Inventories	119.47	121.36
(b) Financial assets		
(i) Trade receivables	682.80	307.16
(ii) Cash and cash equivalents	3.19	25.18
(iii) Bank balances other than (ii) above	2.70	2.58
(iv) Loans	249.67	500.34
(v) Other financial asset	40.50	2.98
(c) Other current assets	69.51	63.21
Total Current Assets	1,167.84	1,022.81
TOTAL- ASSETS	5,747.28	5,777.94
II. EQUITY AND LIABILITIES :		
Equity		
(a) Equity share capital	13.87	13.85
(b) Other equity	3,274.55	3,181.61
Total equity	3,288.42	3,195.46
Non Current Liabilities		
(a) Financial liabilities		
(i) Borrowings	186.60	797.62
(ii) Lease Liabilities	17.01	19.72
(b) Other non-current liabilities	0.37	0.48
(c) Provisions	46.93	46.93
Total Non Current Liabilities	250.91	864.75
Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	1,766.23	1,277.94
(ii) Lease liabilities	6.53	5.86
(iii) Trade payables		
A) Total outstanding dues of micro enterprises and small enterprises	9.85	5.13
B) Total outstanding dues of creditors other than micro enterprises and small enterprises	291.38	214.22
(iv) Other financial liabilities	75.90	160.87
(b) Other current liabilities	19.05	25.91
(c) Provisions	30.97	27.80
(d) Income tax liabilities (net)	8.04	-
Total Current liabilities	2,207.95	1,717.73
Total liabilities	2,458.86	2,582.48
TOTAL- EQUITY AND LIABILITIES	5,747.28	5,777.94



Unaudited Statement of Standalone Cash Flows for the half year ended September 30, 2026

[Rs in Crore]

Particulars	For the half year ended	
	September 30, 2026	September 30, 2025
	(Unaudited)	(Unaudited)
A. Cash flow from operating activities		
Profit before tax	147.66	390.93
Adjustments for :		
Depreciation and amortisation expense	80.86	76.90
Net Loss on property plant and equipment	(0.02)	0.03
Finance costs	84.22	91.64
Interest income	(35.72)	(35.88)
Deferred capital subsidy	(0.19)	(0.23)
Net (gain) on sale of investments carried at fair value through profit or loss	(0.47)	(0.68)
Share based payment expense	4.40	4.00
Operating profit before working capital changes	280.74	526.71
Changes in working capital:		
Adjustments for (increase) / decrease in operating assets:		
Trade receivables	(375.64)	(434.31)
Inventories	1.89	92.85
Financial assets	(2.76)	(0.31)
Other assets	(1.25)	39.52
Adjustments for increase / (decrease) in operating liabilities:		
Trade payables	81.86	34.09
Financial liabilities	(0.31)	0.73
Provisions	3.50	(32.66)
Other liabilities	(6.68)	(4.68)
Cash (used in) / generated from operations	(18.65)	221.94
Net income tax paid	(16.68)	(25.55)
Net cash flow from operating activities (A)	(35.33)	196.39
B. Cash flow from investing activities		
Purchase of property, plant and equipment (including intangible assets, intangible assets under development, capital advances and capital creditors)	(19.96)	(22.37)
Proceeds from sale of property plant and equipment	-	0.09
Consideration paid towards business combination	(39.00)	-
Proceeds from redemption of mutual funds (net)	0.47	0.68
Proceeds from redemption of investment in bonds	-	0.51
Loan given to subsidiaries	(350.98)	(285.20)
Loan repaid by subsidiaries	506.61	14.50
Loan given to others received back	-	(0.12)
Proceeds of Bank balances not considered as cash and cash equivalents	(0.12)	5.27
Interest income	0.55	0.68
Net cash from/ (used in) investing activities (B)	97.57	(285.96)
C. Cash flow from financing activities		
Proceeds/(repayment) from short term borrowings (net)	(119.28)	61.00
Proceeds of long term borrowings	108.50	-
Repayment of long term borrowings	(117.14)	(111.33)
Consideration received from sales of investment in subsidiaries	261.29	209.75
Proceeds of borrowings from subsidiaries	94.46	9.10
Repayment of borrowings to subsidiaries	(89.27)	(10.92)
Interest paid	(130.41)	(141.20)
Payment for lease liability (including interest)	(3.86)	(3.82)
Proceeds from issue of equity share capital (employee stock options plan)	11.36	3.07
Dividend paid	(99.88)	-
Net cash flow from/ (used in) financing activities (C)	(84.23)	15.65
Net increase/(decrease) in cash and cash equivalents (A+B+C)	(21.99)	(73.92)
Cash and cash equivalents at the beginning of the period	25.18	84.34
Cash and cash equivalents at end of the period	3.19	10.42



Additional information pursuant to Regulation 52(4) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 as amended for the quarter and half year ended September 30, 2026

Particulars	Standalone					
	For quarter ended			For half year ended		For year ended
	September 30, 2026 (Unaudited)	June 30, 2026 (Unaudited)	September 30, 2025 (Unaudited)	September 30, 2026 (Unaudited)	September 30, 2025 (Unaudited)	March 31, 2026 (Audited)
Debt – Equity Ratio (in times) (Total Debt(including lease liabilities)/Total Equity)	0.60	0.62	0.79	0.60	0.79	0.66
Debt Service Coverage Ratio (in times) (Profit after tax-Other income+ Depreciation and amortisation expense+Finance Costs+Committed Principal repayments made during the quarter/ period for long term loans/Finance Costs +Committed Principal repayments made during the period for long term loans)	2.49	1.61	2.61	2.05	2.38	1.74
Interest service coverage ratio (in times) (Earnings before exceptional items, Interest and Tax/Finance Costs)	3.84	2.52	6.05	3.18	5.27	3.10
Outstanding redeemable preference shares (quantity and value)	NA	NA	NA	NA	NA	NA
Capital redemption reserve/debenture redemption reserve (Rs in crore)	0.17	0.17	0.17	0.17	0.17	0.17
Net worth (Rs in crore)	3,288.42	3,148.45	2,770.57	3,288.42	2,770.57	3,195.46
Net profit after tax (Rs in crore)	129.15	48.30	149.57	177.46	249.56	244.05
Earnings/ (loss) per share						
Basic	9.32	3.49	10.98	12.81	18.32	17.86
Diluted	9.31	3.48	10.96	12.80	18.29	17.83
Current Ratio (in times) (Current Assets/Current Liabilities)	0.53	0.47	1.00	0.53	1.00	0.60
Long term debt to working capital (in times) (Long-term borrowing+Lease liabilities including its current maturity)/Current Assets	4.07	5.11	7.52	4.07	7.52	11.28
Current liabilities (excluding current maturity) Bad debts to account receivable ratio (in times) (Bad debts/ Trade receivables)	Nil	Nil	Nil	Nil	Nil	Nil
Current liability ratio (in times) (Current liabilities/Total liabilities)	0.90	0.91	0.41	0.90	0.41	0.67
Total debts to total assets (in times) (Total Debt (including lease liabilities)/Total Assets)	0.34	0.36	0.40	0.34	0.40	0.36
Debtors' turnover* (in times) (Sales/ Trade receivables)	2.17	3.04	2.97	2.17	2.97	5.79
Inventory Turnover* (in times) (Cost of goods sold/Average Inventory)	5.11	5.29	4.89	5.11	4.89	4.01
Operating margin percent (Earnings before exceptional items, Interest and Tax/Revenue from Operations)	33.48%	23.94%	43.22%	28.91%	39.26%	30.53%
Net profit margin percent (Profit after tax/Revenue from Operations)	26.78%	10.88%	22.99%	19.16%	20.30%	13.40%

*Quarterly ratios based on trailing twelve months values.



Notes to unaudited Standalone Financial results

- 1 The above statement of unaudited Standalone Financial results ("the Statement") have been recommended by the Audit Committee and approved by the Board of Directors at their meetings held on October 26, 2026.
- 2 The Unaudited Standalone Financial results of the Company have been prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards ('Ind AS') 34, Interim Financial Reporting (Ind AS 34) as prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (as amended).
- 3 The Company has issued and allotted 1,95,682 ordinary shares of Rs 1 each under the Company's Employee Stock Option Scheme 2021 for the half year ended September 30, 2026.
- 4 (A) Exceptional items for the period ended September 30, 2026 comprise of settlement with customers for supply of products, which were launched at risk in earlier periods. The Company has recognised a write down of amounts due from such customers of Rs. 35.90 Crores (net of collections, provisions made in the past) as part of such settlement during the quarter and half year ended September 30, 2026.
(B) Effective November 21, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability and leave liability arising out of past service cost by Rs 14.67 Crores primarily arising due to change in definition of "wages" for employees and contract labours. The Company has presented such incremental impact under "Exceptional Item" in the standalone financial results for the year ended March 31, 2026.
- 5 The Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
- 6 During the year ended March 31, 2026, the Company has completed acquisition of the Branded Probiotics Business from Velbiom Probiotics Private Limited for a consideration of Rs 50 Crores on a slump sale basis. The acquisition was completed on March 31, 2026. The Company is in the process of making final determination of fair values of identified assets and liabilities for the purpose of purchase price allocation.



For Eris Lifesciences Limited,

A handwritten signature in black ink, appearing to read "Amit Bakshi".

Amit Bakshi
Chairman and Managing Director
DIN : 01250925

Place: Ahmedabad
Date: October 26, 2026